MaxCyte (MXCT)
(Delayed Data from NSDQ)
$4.49 USD
+0.03 (0.67%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $4.52 +0.03 (0.67%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MXCT 4.49 +0.03(0.67%)
Will MXCT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MXCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MXCT
Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
MXCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
Qiagen (QGEN) Surpasses Q2 Earnings and Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates
Other News for MXCT
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
MaxCyte Releases Key Annual Report for 2023
Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT)
MaxCyte Awards Stock Options and RSUs to Directors
MaxCyte AGM Concludes with Positive Outcomes